Arnicare Gel Value Pack
- Manufacturer
- Laboratoires Boiron | Boiron Inc. | Boiron
- Effective date
- 2023-11-27
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 13
- Source
- full-release
- Hydrated at
- 2026-06-01 02:24:56
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
OTC - ACTIVE INGREDIENT SECTION
Active ingredients**
Arnicare Gel: Arnica Montana 1X HPUS 7%
Arnica 30C pellets: (in each pellet) Arnica Montana 30C HPUS (0.443 mg)
The letters "HPUS" indicate that the components in this product are officially monographed in the Homeopathic Pharmacopoeia of the United States.
INDICATIONS & USAGE SECTION
Uses*
temporarily relieves muscle pain and stiffness due to:
- minor injuries
- overexertion
- falls
reduces symptoms of bruising such as:
- pain
- swelling
- discoloration
OTC - PURPOSE SECTION
Purpose*
Arnicare Gel: Arnica Montana 1X HPUS 7% ..... Relieves muscle pain & stiffness, swelling from injuries, discoloration from bruises
Arnica 30C Pellets: Arnica montana 30C HPUS .......... Relieves muscle pain & stiffness, swelling from injuries, discoloration from bruises
WARNINGS SECTION
Arnicare Gel: For external use only.
OTC - DO NOT USE SECTION
Do not use if you are allergic to Arnica montana or to any of this product's inactive ingredients.
OTC - WHEN USING SECTION
When using this product
- avoid contact with eyes, mucous membranes, wounds, damaged or irritated skin
- use only as directed
- dryness or irritation may occur
- do not tightly wrap or bandage the treated area
- do not apply heat or ice to the treated area immediately before or after use.
OTC - STOP USE SECTION
Stop use and ask a doctor if
condition persists for more than 3 days or worsens
symptoms clear up and occur again within a few days.
ARNICA 30C PELLETS:
Stop use and ask a doctor if symptoms persist for more than 3 days or worsen.
OTC - PREGNANCY OR BREAST FEEDING SECTION
If pregnant or breastfeeding, ask a health professional before use.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
DOSAGE & ADMINISTRATION SECTION
Directions
ARNICARE GEL: Apply a thin layer of Arnicare Gel to affected area as soon as possible after minor injury. Repeat 3 times a day or as needed. If heat or ice is applied, wait 5 minutes before applying Arnicare Gel.
ARNICA 30C PELLETS: At the onset of symptoms, dissolve 5 pellets under the tongue 3 times a day until symptoms are relieved or as directed by a doctor.
INACTIVE INGREDIENT SECTION
ARNICARE GEL: alcohol, carbomer, purified water, sodium hydroxide
ARNICA 30C PELLETS: lactose, sucrose.
OTC - QUESTIONS SECTION
Arnicare.com
BoironUSA.com
Info@Boiron.com
1-800-BOIRON-1
1-800-264-7661
SPL UNCLASSIFIED SECTION
do not use if glued carton end flaps are open, if the tube seal is broken, or if pellet dispenser seal is broken
Quickly absorbed, non-greasy, fragrance-free, non-drowsy, no known drug interactions
Pain Relief*
Muscle Pain & Stiffness Swelling from Injuries Bruises*
Local & General Pain
Combine for Total Relief
Gel: 1 tube 2.6 oz (75g)
Pellets: + approx. 80 pellets
How to dispense pellets? Turn tube upside down. Twist until 5 pellets are dispensed into cap. Carefully remove the cap and use it to pour pellets under the tongue.
*CLAIMS BASED ON TRADITIONAL HOMEOPATHIC PRACTICE NOT ACCEPTED MEDICAL EVIDENCE. NOT FDA EVALUATED.
**C,K,CK, and X are homeopathic dilutions: see BoironUSA.com/info for details.
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0220-9042-79 | Arnicare Value Pack | 1 in 1 KIT | KIT | 1 | 13 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0220-9000-54 | GM - Gram | 0220-9000 | cff869c1-d2d4-4a6b-b3c8-538129f7e9b5 | 1 | 2019-10-07 |
| 0220-9000-59 | GM - Gram | 0220-9000 | e3199ec0-b61f-46c0-bdc3-b278542c58fb | 1 | 2021-02-05 |
| 0220-9000-84 | GM - Gram | 0220-9000 | 5ecb73ed-c511-4676-8bff-f136e195c0d1 | 1 | 2021-02-05 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ARNICA MONTANA | ACTIVE INGREDIENT | O80TY208ZW | 8 | |
| ARNICA MONTANA | ACTIVE MOIETY | O80TY208ZW | 8 | |
| ALCOHOL | INACTIVE INGREDIENT | 3K9958V90M | 8 | |
| CARBOMER HOMOPOLYMER TYPE C | INACTIVE INGREDIENT | 4Q93RCW27E | 8 | |
| DIMETHICONE | INACTIVE INGREDIENT | 92RU3N3Y1O | 8 | |
| LACTOSE | INACTIVE INGREDIENT | J2B2A4N98G | 8 | |
| SODIUM HYDROXIDE | INACTIVE INGREDIENT | 55X04QC32I | 8 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 8 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 8 |
Products#
Every source-derived product name is available through these pages.
- Arnicare Value Pack
- ARNICA MONTANA
- Arnica
- SUCROSE
- LACTOSE
- Arnicare
- ALCOHOL
- DIMETHICONE
- WATER
- SODIUM HYDROXIDE
- CARBOMER HOMOPOLYMER TYPE C
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 0220-9042 | 0220-9042-79 |
| 0220-0508 | |
| 0220-9000 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| SUCROSE | C151H8M554 | IACT |
| LACTOSE | J2B2A4N98G | IACT |
| ARNICA MONTANA | O80TY208ZW | ACTIB |
| ALCOHOL | 3K9958V90M | IACT |
| DIMETHICONE | 92RU3N3Y1O | IACT |
| WATER | 059QF0KO0R | IACT |
| SODIUM HYDROXIDE | 55X04QC32I | IACT |
| CARBOMER HOMOPOLYMER TYPE C | 4Q93RCW27E | IACT |
| ARNICA MONTANA | O80TY208ZW | ACTIB |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SUCROSE | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SOLUTION / ORAL | 42596 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / ORAL | 4249 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL / TOPICAL | 9971 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, EXTENDED RELEASE / ORAL | 284.54 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, DELAYED RELEASE / ORAL | 160 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED / ORAL | 145 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, CHEWABLE / ORAL | 7258 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SOLUTION / ORAL | 38666 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED PELLETS / ORAL | 59.8 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Arnica | ARNICA MONTANA | Laboratoires Boiron | 1ce3fd1f-24f8-491c-a0ae-087ea3d20040 | 2025-12-29 | 0220-0508 | |
| Arnicare | ARNICA MONTANA | Laboratoires Boiron | ce519152-e6fb-42e3-8fd4-f819476ebd86 | 2025-07-21 | Warnings | 0220-9000 |
| Arnicare Value Pack | ARNICA MONTANA | Laboratoires Boiron | bc842386-e41c-4303-b27f-1642771ed1a4 | 2023-11-27 | Warnings | 0220-9042-79 0220-9042 00220904279 0b294e1a-d6e5-e2fd-e063-6394a90a05c4 bc842386-e41c-4303-b27f-1642771ed1a4 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.

